A growing body of evidence shows that gamma-hydroxybutyric acid (GHB) is an addictive substance. Its precursors gammabutyrolactone (GBL) and 1,4-butanediol (1,4-BD) show the same properties and may pose even more risks due to different pharmacokinetics. There are indications that problematic GHB use is increasing in the European Union. This review investigates the existing literature on the neurochemistry of GHB and its precursors, their acute toxicity, addiction potential and withdrawal, the proposed molecular mechanism underlying addiction and the treatment of withdrawal and addiction. Current evidence shows that GHB and its precursors are highly addictive, both in humans and animals, probably through a GABAB receptor related mechanism. Severity of withdrawal symptoms can be considered as a medical emergency. Recent studies suggest that benzodiazepines are not very effective, showing a high treatment resistance, whereas detoxification with pharmaceutical GHB proved to be successful. However, relapse in GHB use is frequent and more research is warranted on relapse prevention. This might aid medical practitioners in the field and improve general understanding of the severity of addiction to GHB, GBL and 1,4-BD.
INTRODUCTION
Gamma-hydroxybutyric acid (GHB), a precursor of gammaaminobutyric acid (GABA), was developed as an anesthetic in the early 1960s [1] . This application was possible because, unlike GABA, GHB can pass the blood brain barrier. However, GHB became obsolete as an anesthetic due to undesirable side effects such as vomiting and severe cramps and its narrow dose-response margin [2] . In 2005, GHB was approved by the FDA (United States Food and Drug Administration) for the treatment of narcolepsy and in some countries it is also used in the treatment of withdrawal symptoms in alcoholics [3] [4] [5] [6] . Since the 1990s, GHB has been increasingly recognized as a substance of abuse in recreational settings, due to its euphoric and sexually stimulating effects [2, 7] . As a consequence, GHB was listed as an illegal drug in several countries [8] . Not much later, the GHB precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) emerged as legal alternatives to GHB exerting similar effects. These GHB-like psychotropic effects are induced because both compounds are rapidly converted to GHB [9, 10] , following oral use of GBL [10] [11] [12] or 1,4-BD [13, 14] . GHB, GBL and 1,4-BD are cheap and easily purchased via the Internet [15] .
GHB and its precursors show a biphasic effect pattern, the stimulant-like effects and euphoria are quickly followed by sedation as blood concentrations rise. There is a fine line between the dose where desired effects are experienced and overdose symptoms occur [16] . Overdose symptoms include ataxia, seizures, vomiting, cardiac-, respiratory-and CNS depression and, eventually, reversible coma [17] . It is therefore not surprising that inexperienced use of GHB and its precursors has led to a worldwide documentation on their toxicity [11, [17] [18] [19] [20] [21] [22] . Furthermore, the probability of intoxication increases when other sedatives are combined with GHB, e.g. alcohol or ketamine [23] [24] [25] . Last year prevalence (current use) of GHB in the Netherlands in 2009 was about 0.4% (70,000) [26] . Estimations from Australia and the United Kingdom indicate lower prevalences of current use of 0.1% among the general population [27, 28] . However, there are indications that problematic GHB (and GBL) use is rapidly increasing in the European Union [15] . In the Netherlands, emergency department (ED) presentations of GHB intoxications increased from 300 ED treatments in 2004 to 1200 in 2009 [26] . A similar trend, albeit more modest, was seen in the United Kingdom between 2006 and 2010 [29] . Also, in general, the nature of GHB intoxications at EDs was more serious than that with most other drugs of abuse, like ecstasy or cannabis [30] . Likewise, the number of information requests for GHB and GBL intoxication has risen steeply and ranks second after cannabis in 2011 and, especially, information requests by medical practitioners about GBL intoxication increased sharply from 5% in 2008 to 14% in 2011 [26] . In addition, various international ED studies reported GHB/GBL intoxication as one of the major forms of drug overdosing [31] [32] [33] [34] [35] . Despite these hazards, GHB and its precursors are generally considered as cheap, safe and harmless by recreational drug users [36, 37] . Moreover, GHB was long considered not to be addictive [38] .
However, there is convincing evidence now that frequent GHB use can rapidly cause dependence and withdrawal [39, 40] . First of all, preclinical evidence of the dependence potential of GHB and its precursors has recently been accumulating based on animal studies [41] [42] [43] [44] [45] . Similarily, in humans, physical dependence has been described within weeks of frequent and heavy use [46] . Without treatment, withdrawal is characterized by symptoms of variable severity and in order to avoid these symptoms users may end up taking GHB around the clock [38, 39, [47] [48] [49] [50] .
This review investigates the existing literature on the neurochemistry, addiction potential and treatment of GHB, GBL and 1,4-BD addiction. Starting with the basic metabolism, pharmacokinetics and pharmacodynamics of these substances, the review will then briefly show current clinical applications of these substances as well as their recreational use that followed and acute toxicity. The main focus of this review is on the addictive properties of these substances, the molecular mechanisms involved in GHB addiction supported by the most recent evidence and the treatment of withdrawal in patients with GHB, GBL and 1,4-BD addiction. The purpose of this review is to improve understanding of the severity of addiction to GHB and its precursors and a critical appraisal of current evidence.
METABOLISM OF GHB, GBL AND 1,4-BD
GHB is structurally related to GABA, the main inhibitory neurotransmitter in the CNS. It occurs naturally in the brain and is both a "precursor" and a metabolite of GABA [38] . It is found at very low concentrations in the brain [51, 52] . It is derived from its metabolic precursor GABA by conversion into succinic semialdehyde via GABA transaminase (Fig. (1) ) [38] . Succinic semialdehyde is subsequently converted into GHB by succinic semialdehyde reductase. In a metabolic feedback loop, GHB may be degradated by the action of GHB dehydrogenase into succinic semialdehyde and then converted by GABA transaminase into GABA again. Nevertheless, the primary degradation pathway of GHB seems to be into succinate through the conversion of succinic semialdehyde by the enzyme succinic semialdehyde dehydrogenase [17] . Additional GHB can be formed by the oxidation of 1,4-BD via alcohol dehydrogenase into gamma-hydroxybutyraldehyde, which is metabolized by aldehyde dehydrogenase to GHB [53] . Also serving as a prodrug, exogenous GBL is converted into GHB by a lactonase that is present in liver and serum, but not in the brain [17] .
PHARMACOKINETICS
After oral intake, GHB is easily absorbed and peak concentrations in the blood and brain occur within 1 hour. The half-life is 30-60 minutes, while GHB is usually fully eliminated from the blood within 6 hours [54] . Although the subjective effects of GBL and 1,4-BD seem more or less equivalent to those of GHB, they show a different pharmacokinetic profile. GBL is even more easily absorbed than GHB [10] and is converted rapidly in the periphery, resulting in a higher bioavailable level of GHB after administration of GBL than an equivalent dose GHB [55] . Because of its higher bioavailability and more rapid absorbtion, GBL is regarded to be more potent than GHB, but with a shorter duration of effects. Conversely, due to somewhat slower elimination, it has been suggested that 1,4-BD has a longer duration of effects than GHB [56, 57] . Like GHB, it is rapidly absorbed with a peak concentration of GHB after 25 minutes in healthy human volunteers [54] . In baboons, both GBL and 1,4-BD were shown to give a higher maximum concentration of GHB and shorter time to reach this concentration than GHB itself [58] . Pharmacokinetic differences could imply that users of GBL or 1,4-BD are at different risks of overdosing than users of GHB because the speed of action of these substances is different . In addition, GBL is more lipophilic than GHB and the enzyme lactonase can vary genetically between individuals, which means that GBL can display even more unpredictable results, especially in first-time users [59] .
NEUROBIOLOGICAL TARGETS: GHB-AND GABA RE-CEPTOR SYSTEMS
GHB has been proposed as a neurotransmitter or neuromodulator in the brain [51, 60] . In both rodent and man, receptors have been identified to which GHB binds with high affinity [61, 62] . GHB receptors were shown to be abundant in the hippocampus and cortex [61] [62] [63] . These are likely to be G-protein-coupled receptors and respond to micromolar (physiological) concentrations of GHB, but rapidly desensitize at doses exceeding these physiological concentrations [62] . In these micromolar concentrations, the presynaptic GHB receptor probably inhibits GABA release and its action is thus excitatory [38, 64] . In addition, glutamate release is also affected through presynaptic GHB heteroreceptors and glutamatergic NMDA receptors appear to be downregulated by GHB, impairing spatial learning [38] . The precise biological function of the GHB receptor remains unknown.
GHB also binds to the GABA B receptors, but with low affinity [38, 62] . Endogenous concentrations of GHB are too low to activate these receptors. However, when concentrations of GHB in the brain rise as a result of systemic administration (like in settings of drug use or involuntary administration in rape assault cases), the GHB receptor desensitizes and GHB acts as a competitive agonist at the presynaptic GABA B receptors. These presynaptic GABA B receptors can be subdivided into autoreceptors, at which GHB has an inhibitory effect on GABA release, and heteroreceptors, which inhibit the release of most other neurotransmitters [38] . It is mainly through the GABA B receptor that exogenous GHB exerts its typical pharmacologic, clinical, behavioral, and toxicologic effects [17, 38] . This was ascertained by experiments where it was shown that GABA B antagonists, but not GHB antagonists, provided protection from GHB's typical effects in rodents, like sedation, hypothermia, distorted coordination, hypolocomotion and absence seizure-like activity [64, 65] . Moreover, these effects were completely absent in GABA B knockout mice after GHB or GBL application [66] . In animals and humans, the dual actions at these two receptor systems could explain the sudden awakening after several hours of GHBinduced deep sleep, because over time the concentration of GHB in brain decreases to a level at which predominantly GHB receptors are activated and excitation remains [52] . Also, in animal drug discrimination studies, mainly GABA B agonists, like baclofen, were able to evoke the same responses as GHB [67] . Discriminative stimulus effect studies can be used to study whether or not different substances evoke similar effects or whether certain substances can (partially) replace other substances. These studies can also be used to uncover common mechanistic pathways.
Selective GABA B antagonism diminished these discriminative stimulus effects, whereas antagonists of the GHB receptor did not. However, the difference in effects between baclofen and GHB has led researchers to hypothesize about the possibility for two receptor subtypes of GABA B . Additional complexity of GHB's actions is added by the fact that it is partly degraded into GABA in the brain. So, it was argued that GHB activates the GABA system in at least three independent ways: (1) as low-affinity GABA B -ergic agonist, (2) promoting GABA release and (3) as a precursor of GABA [38] . Figure 2 tries to capture the interactions of GHB with its respective receptor systems.
Fig. (2).
The pharmacodynamics of GHB and its putative targets in the brain. Exogenously administered 1,4-BD and GBL are metabolized into GHB via enzymatic pathways in the body. GHB is an agonist at both the GHB-and GABAB receptors. GHB is degraded and metabolized downstream into GABA, which subsequently binds to its own receptors, GABAA and GABAB.
CLINICAL APPLICATIONS OF GHB
Nowadays, GHB is not commonly used as an anesthetic anymore. However, there are some other medical applications for its use, GHB (as Xyrem ® ) is indicated to treat insomnia in narcolepsy patients [68] and alcohol withdrawal symptoms in alcohol dependent patients [4] . GHB reduces the symptoms of narcolepsy by stimulating the slow-wave, "deep sleep" with no effect on REM sleep [69] . The typical dose for this clinical indication is 4.5 g/ daily p.o., divided over two doses of 2.25 g at bed time and 4 hours later [70] . In some countries, GHB has also been used for the treatment of opioid withdrawal symptoms, alcohol withdrawal symptoms and for the prevention of relapse to alcohol use in alcohol dependent patients [40, 71, 72] . Clinical trials demonstrated that GHB, from three to six daily administrations (50-100 mg/kg), was able to suppress alcohol withdrawal and facilitated abstinence from alcohol [4] . However, serious concern was expressed in another systematic review about the risk of developing GHB dependence, which was not adequately investigated in those previous clinical trials [73] .
The virtual absence of abuse liability of GHB in clinical trails of narcolepsy patients or alcoholics remains a challenging issue [4, 74, 75] . Approximately, only one case for every 2,600 narcolepsy patients treated fulfilled DSM-IV criteria for substance abuse [76] . There could be a number of possible explanations for this. Pharmaceutical GHB use for narcolepsy is prescribed in a medical setting of strictly nightly doses of up to 4.5 g to 9.0 g/ a day, fairly low doses compared to the doses used by frequent recreational users. Another proposed explanation is that there are important differences between illicit GHB and the pharmaceutical product in accessibility and purity [76] . Illicitly synthesized GHB often contains uncontrolled, and sometimes substantial higher than expected, concentrations or might still contain a considerable amount of GBL for instance. This could have profound effects on its potency and abuse liability. Also, combined use of alcohol and other CNS depressants is strongly discouraged in narcolepsy patients, whereas recreational and problematic users usually combine GHB with other substances [77] [78] [79] . Finally differences in addiction vulnerability between medical and recreational users may play an important role.
For the treatment of alcoholism, craving for GHB was found to be more frequent, although still a limited phenomenon (about 10%) [74] . Interestingly, when craving for and abuse of GHB was investigated among different types of alcoholics, craving for GHB was higher in those with previous cocaine dependence than in "pure" alcoholics, but craving for GHB did not differ between "pure" alcoholics and those with previous heroin dependence. According to the current insights, this may be due to effects on the dopamine (DA) system. Chronic exposure to cocaine reduces GABA B receptor activity in the mesocorticolimbic system [80, 81] . GHB may upregulate DA in these former cocaine using alcoholics through reactivation of the GABA B receptor, with a higher propensity for developing craving for and abuse of GHB.
RECREATIONAL USE OF GHB 6.1. Prevalence of use
Since the 1990s, GHB, GBL and 1,4-BD have been increasingly used as recreational drugs [2] for its increased euphoria, relaxation, increased sociability and enhanced sensuality [72] . For instance, in the Netherlands the use of GHB gradually increased over the last decade and became the most popular recreational anesthetic drug with a last year prevalence of 0.4% in the general population in 2009 [26, 82] . GHB users are generally young adults (18-30 years) [32, 83, 84] . In the ESPAD study, a population survey performed amongst 15-16 year old European college students, a life-time prevalence of GHB use was reported ranging from 1% to 2% [85] . Lifetime and last month prevalence of GHB use in the Australian population aged 14 years or older was 0.5% and 0.1%, respectively with a peak between 20 and 29 years [28, 86] . However, GHB use appears to start at a much younger age (16-17 years) [87] than in 2001, when the average starting age was 24 years [88] . Moreover, European surveys among partygoers show higher prevalence rates of GHB use than in the general population. In a recent survey among visitors of parties and festivals in the Netherlands, last month prevalence of GHB use was 4.6% and lifetime use 14% with a mean age of 23 yrs [89] . A recent survey carried out in the United Kingdom of a group of 2000 clubbers revealed a lifetime prevalence of 15.2% for GHB and 5.8% for GBL use, with last month prevalences of 1.7% and 1.6%, respectively [90] . Between 2005 and 2006, last 4 months prevalence of GHB use among clubbers (mean age 24 yrs) in New York was 5% [91] . In summary, recreational GHB use is on the rise with general GHB use and start of use at a young age.
Characteristics of Ghb Users
In a typology of club drug users in New York City, users of GHB were often characterized as extensive polydrug users with a tendency for sensation seeking and high risk behaviours [77] . Extensive polydrug use was supported by ED studies done in Western Europe [21, 29, 35] and Australia [33] . These studies suggested that these users were rather indiscriminatory of the drugs they used, as long as they got their high. In the Netherlands, in recent years, the use of GHB has shifted from partygoers in the larger cities to a, less typical, broader group of users spread out over more rural areas and use more often outside the party scene [92, 93] . A worrying phenomenon is that these users frequently report passing out (coma) after an unintentional overdose, at home or with friends, and rarely indicate this as problematic [87] . This is supported by previous emergency department (ED) studies, showing frequent hospitalization after a GHB overdosis [21, 36, 94] . The subjects under study reported using GHB several times a week and even several times a day [21] . This also raises the question whether these users may be compulsive users or addicted.
Research into the source of obtaining GHB revealed that most users get it from friends or make it themselves [79, 87, 95] . It may very well be that the relative ease to manufacture GHB and the free accessibility of its components through internet wholesale (cleaning products, usually pure GBL) leads the drug to be around in abundance and its use relatively unrestrained. Finally, GHB is a very cheap drug (0.5 euro per dose) and often handed out for free by friends. Partners, colleagues or friends are often unaware of heavy use of GHB by their peers as frequent users are able to function normally and generally show no physical signs of use, letting frequent use go virtually undetected. Therefore, it could be that this may have led to a certain group that was vulnerable for the development of GHB abuse and addiction.
PROBLEMATIC USE: ACUTE TOXICITY 7.1. Clinical Symptoms
GHB, GBL, and 1,4-BD have all been described as toxic substances [17, 31] . In the cases of GBL and 1,4-BD this is largely ascribed to the pharmacological conversion to GHB. GBL is a biologically inactive compound and 1,4-BD has proven to have a moderate toxicity by itself. From a large body of international case studies, clinical intoxication symptoms have been reported [19, 22, [31] [32] [33] [34] [35] . Most commonly seen were CNS depression associated with bradycardia, hypotension and hypothermia. In addition, other symptoms include aggression, ataxia, amnesia, vomiting, somnolence, apnoea, seizures, asphyxia and coma [31, 38, 96] . Most of these symptoms usually resolve within 4 to 8 hours, probably due to the short elimination time of GHB and its precursors and metabolites [54] . Some of the symptoms that were reported in cases of GHB toxicity may be related to the polydrug use, mainly concurrent use of ethanol has been described to pose more risks than the use of GHB or its precursors alone [31] . Users who combined GHB with ethanol showed more severe complications related to GHB use, both in the clinic [21] and in a double-blind, placebo-controlled, study [54] . Increased toxicity was not the result of a pharmacokinetic interaction between GHB and ethanol. Similarly, the probability of inducing a coma may be increased by combined use with other sedatives [24] . On the other hand, sedative effects of GHB might be counteracted by the combined use of stimulants, such as cocaine or amphetamine.
Clinical Case Studies and Epidemiology
Many ED case studies mention GHB related overdose and subsequent coma as major reason for drug use related hospitalization [19, 22, [31] [32] [33] [34] [35] . In the Netherlands, it is estimated that 20% of all drug related hospitalizations was due to GHB [26] . This is a very high percentage, considering that prevalence of GHB use in relatively modest in comparison with other drugs. In Melbourne, Australia, 618 GHB-related ambulance attendances were recorded during 2001 to 2005 with an increase of 4% per month, a higher rate of increase than for heroin overdoses [97] . In addition, 90% of patients were hospitalized, compared to 21% for heroin. However, in most countries estimates are hard to come by and many cases of GHB intoxication are probably overlooked anyway. Many patients and their friends will not report to an ED for assistance and rather "sleep it off" [31] . Also, many cases of GHB intoxication will be misdiagnosed as result of unfamiliarity with the symptoms or confused with ethanol intoxication or another sedative.
A Spanish ED study describing cases from 2000 to 2007 showed that 72% of GHB-intoxicated patients scored 12 on the Glasgow Coma Scale (GCS) [35] . If a low score on the GCS is also accompanied by vomiting, aspiration might follow and aspiration pneumonia, due to the lack of protective airway reflexes [31] . The state of non-responsive coma is defined by a GCS of 3 and this is frequently seen in these ED case series. Usually, monitoring of vital signs suffices and most patients awake rapidly from non-responsive coma to consciousness without hangover or headache. Currently, there is no antidote for GHB overdose symptoms and treatment of acute intoxication is mainly supportive. Intubation and mechanical ventilation are rarely needed in these patients [98] , unless the respiratory system is severely hampered by CNS depression or when patients show clinical indications for it, like vomiting or seizures [31] . Due to the quick absorption of GHB, gastric lavage is not very useful. Administration of extra oxygen has been described and atropine for bradycardia [17] . Sudden awakening and agitation are characteristics that follow after overdose, sometimes sedatives are required to calm the patient down [25] . It has been proposed that physostigmine might reverse some of the clinical symptoms of GHB intoxication, but others have concluded there wasn't enough evidence to recommend this as a clinical therapy. Moreover, the use of physostigmine was even associated with serious adverse events, like atrial fibrillation, bradycardia, pulmonary infiltrates and hypotension [99, 100] .
In addition to these clinical findings, several hundreds of deaths have been mentioned in two different studies from the United States and Europe as a consequence of GHB toxicity and its precursors [19, 22] . Presumably, the actual number is considerably higher, but in many of these cases combined use of GHB with other substances is involved and it is very hard to detect GHB in post-mortem fluids [31] . Therefore, it is difficult to determine a direct causal relation between GHB intoxication and death. In most cases, the cause of death was aspiration and respiratory arrest.
PROBLEMATIC USE: GHB ADDICTION 8.1. Addiction Liability in Humans
Regular GHB use may cause severe dependence and serious withdrawal symptoms upon abrupt discontinuation of chronic, frequent use [39, 40, 46, 101] . Studies on recreational users revealed a high dependence liability in frequent, heavy GHB users [36, 102] . In clinical trials with human subjects GHB displayed greater abuse liability than ethanol [16, 103] . It has been described that intensive/ frequent GHB use (i.e. > 4 times per day, 2-4 weeks and in higher doses) can lead to physical dependence within a few weeks [46] . According to Miró et al. [104] , the dose of GHB associated with dependence is about 18 g per day (with one dose on average being 2.5-3.5 g) and for GBL this is 10 g per day. Interestingly, the majority of patients in treatment for GHB dependence only had a brief history of GHB use, often one or two years, suggesting that dependence to GHB indeed develops rapidly [12, 39, 46, 49] .
Withdrawal in Humans
Upon drug discontinuation moderate GHB, GBL or 1,4-BD users will usually experience a mild withdrawal syndrome, but withdrawal can be more severe in chronic and heavy users of GHB, GBL or 1,4-BD. The withdrawal symptoms of GHB and its precursors start quickly (1 to 6 hours after the last dose) and can last 5-21 days in severe cases [50, 106] . This withdrawal syndrome is much more serious than previously assumed and certain symptoms are similar to that seen with other CNS depressants, like benzodiazepines, alcohol or barbiturates [40, [47] [48] [49] . In frequent and heavy users withdrawal symptoms include tremors, cardiac arrhythmias, hypertension, delirium, hallucinations and seizures [107] [108] [109] . Dependence severity was strongly associated with sleep problems [79] , which may persist for weeks after GBL detoxification [110] . In terms of subjective severity, GHB withdrawal is often experienced to be just as severe as withdrawal from heroin and alcohol [39, 111] . However, the objective risks and symptoms of GHB withdrawal may vary substantially from those associated with heroin withdrawal, since GHB withdrawal has been associated with a rapid onset of life-threatening complications in some occasions [47, 107, 109] . The rapid onset of GHB withdrawal can at least partly be explained by its short half-life (T 1/2 of 20-45 min). The severity of withdrawal symptoms can urge users and clinicians treating GHB withdrawal by maintaining their GHB levels by redosing every two hours, around the clock (GHB intake every 30 minutes has been reported) [38] .
Experimental Evidence: Animal DATa
Early drug discrimination studies indicated GHB as an addictive substance; GHB, GBL and 1,4-BD elicited similar responses in rats as reinforcers like ethanol or diazepam, known GABA A agonists [57, 112, 113] . GABA B agonists, like baclofen, were also able to partly mimick responses to GHB. Nevertheless, animals were clearly able to distinguish ethanol, baclofen or diazepam from GHB, and no other substance could really substitute for GHB, indicating that multiple receptors were probably involved in these discriminative stimulus effects in rats [76, 114] . Animals also showed conditioned place preference after chronic administration of GHB, which suggests reinforcing effects of GHB [115] . Other lines of evidence showed that GHB is readily self-administered by rats and mice, and rats that were chronically administered GHB showed tolerance and withdrawal [116] [117] [118] . Tolerance to GHB has been demonstrated after 3-6 days of daily administration in rats [117, 118] . In addition, GHB and alcohol showed cross-tolerance [105] .
Perhaps the most compelling evidence for GHB, GBL and 1,4-BD as addictive substances comes from experiments executed in the laboratories of Weerts and colleagues from the John Hopkins University. They did a series of experiments in baboons, a nonhuman primate that shows a close genetic proximity to humans. Physical dependence was shown after chronic intragastric administration of GHB, GBL and 1,4-BD [41] [42] [43] [44] . Chronic GHB (350-750 mg/kg), GBL (400-600 mg/kg) or 1,4-BD (600 mg/kg) decreased feeding behavior, disrupted performance and produced sedation and muscle relaxation. In these experiments, discontinuation of administration and GABA B antagonism produced abrupt withdrawal, not antagonism of the benzodiazepine site of the GABA A receptor with flumazenil. In more recent experiments, self-administration was established in baboons that were offered GHB (3.2-178 mg/kg/injection), GBL (10-130 mg/kg/injection) and 1,4-BD (10-100 mg/kg/injection) [43, 45] .
GHB Addiction and Dopamine: Molecular Targets
Converging evidence suggests that virtually all known addictive substances induce their reinforcing properties through activation of the mesocorticolimbic dopamine (DA) system, so this brain circuitry has been a logical target for GHB's actions [38, 119] . The mesocorticolimbic DA circuitry is composed of the ventral tegmental area, nucleus accumbens and prefrontal cortex. GHB alters dopaminergic activity in the brain, either by increasing or decreasing the amount of DA released [120] [121] [122] , and it decreases firing of dopaminergic neurons in the striatum [123, 124] . Chronic treatment of rats with GHB results in an increase of mRNA expression of dopamine D 1 and D 2 receptors in brain regions that are rich in GHB receptors [125] and the development of tolerance to the effect of GHB on brain dopamine levels. In rats, low doses of GHB (50-400 mg/kg) increase dopaminergic cell firing in the substantia nigra, whereas higher doses (1000-1500 mg/kg) inhibit dopaminergic cell firing [126] . However, in rats, after an initial inhibitory phase, DA release increases, probably due to GHB receptor re-activation [52] . This complex mechanism could partly explain the dual effects of GHB observed in recreative users i.e. both sedation and stimulation. Although some of the actions on the DA system are mediated through high affinity of GHB to the GHB receptor, most of it is thought to be mediated via the low affinity of GHB to the GABA B receptors in the mesocorticolimbic DA system [41, 44, 119, 127] .
Classically, addictive drugs cause an increase in the neuronal activity of mesocorticolimbic DA system [119] . However, as was mentioned above, there is an intriguing paradox in GHB's actions on DA as it exerts two opposing actions: at low concentrations GHB stimulates DA release whereas at higher and enduring levels it inhibits DA release [128] [129] [130] . The solution of this apparent paradox lies in the interaction of GHB with GABA B receptors in the mesocorticolimbic dopamine (DA) system. The coupling between the GABA B receptors and the G protein-gated inwardly rectifying potassium channels was found to be more decreased in DA neurons as compared to GABA neurons [131, 132] . This renders GABA neurons more sensitive to GHB's actions than DA neurons. GHB administration may therefore preferentially inhibit GABAergic neurons and the release of GABA in the ventral tegmental area through presynaptic GABA B receptors. The result would be a disinhibition of DA neurons of the ventral tegmental area with increased dopaminergic activity within that circuitry (Fig. (3) ). This mechanism was also supported in a study whereby direct injection of GHB into the ventral tegmental area, but not the nucleus accumbens, induced rewarding properties [42] . It is this disinhibition, leading to DA release, which is thought to be responsible for the addictive properties of GHB and its precursors. However, repetitive exposure to GHB (1) increases the GABA B receptor-potassium channel coupling of DA neurons, which inhibits DA release and (2) causes tolerance to GHB. GHB may even become aversive, which may offer an explanation for its efficacy in treatment of alcohol withdrawal symptoms [74] .
This differential action of GHB on DA and GABA neurons might also help explain why GHB is addictive and baclofen is not [133] . In fact, it does explain various properties of GHB that have remained elusive previously. It explains the limited efficacy of treatment of GHB dependent patients with benzodiazepines. Importantly, it also offers additional avenues for addiction treatment of GHB and its precursors, like preliminary treatment results with baclofen promises [134] . Similarly, GABA B receptor antagonsim may also prove to be useful in treating respiratory depression resulting from GHB overdoses or withdrawal [135] . However, while the GABAergic mediated DA disinhibition hypothesis is plausible for many reasons, there could be alternative routes by which GHB may disinhibit DA neurotransmission, such as the modulation of GHB of the locus coeruleus norepinephrine neurons [136] . Finally, GHBderived GABA interacts with both subtypes of the GABA receptor, which may provide for added complexity of GHB's addictive effects [38] .
TREATMENT OF GHB ADDICTION
Recently, most data about clinical treatment has been assembled in the Netherlands [26, 78, 79, 137] . Probably due to the serious lack of awareness of the risks of GHB, previous to 2009, treatment for GHB dependence was not registered in the Netherlands. But the number of requests for GHB dependence treatment has rapidly increased from 60 in 2007 to 761 in 2011 [137] , leading to public health concern and scientific interest. Most subjects, seeking help for their GHB dependence, were young adults (mean age of 28 yrs; 32% younger than 25 yrs), and relatively more women were dependent on GHB compared to clients that are addicted to other substances of abuse (33%) [137] . This was also confirmed in a sample of 75 inpatients treated for GHB dependence (DUDIT dependence score > 25) where 73% was male and the mean age was 26.8 yrs. In addition, most patients were low educated (78%) and half of them (48%) was unemployed [79] . This unemployement rate was also found for users of GBL in a British study. Ages of these patients were between 21 and 37 years (mean 27.9) and 17 of 19 were male, mostly gay men [110] . All reported daily 'round the clock' use of GBL. Strikingly, almost half of GHB dependent clients in the Netherlands was known by the police for some criminal offence [95] .
The withdrawal syndrome of GHB, GBL or 1,4-BD closely resembles that of other sedative-hypnotic agents [48, 138] . GHB withdrawal is known to cause autonomic dysfunction with severe CNS symptoms [11, 50] . A systematic review [109] on withdrawal from GHB, 1,4-BD and GBL included 27 studies with 57 cases with withdrawal: GHB in 36 cases (63%), 1,4-BD in 3 cases (5%) and GBL in 18 cases (32%). Withdrawal features, similar for all three agents, consisted of tremor (67%), hallucinations (63%), tachycardia (63%), insomnia (58%), anxiety (46%) and hypertension (44%). Seizures and rhabdomyolysis each occurred in 7% of the cases, and death occurred in one patient withdrawing from GHB [50] . In such severe cases of GHB withdrawal, intense treatment with high doses of sedative hypnotics, mostly benzodiazepines, was generally indicated [138] .
Whereas in some instances, GHB withdrawal has responded well to a treatment with benzodiazepines, many patients still showed severe manifestations of withdrawal symptoms and treatment resistance to high doses of benzodiazepines [39, 48, 49, 109, 139] . The doses of diazepam or oxazepam could amount to up to 230 mg or 300 mg a day, respectively [49, 78] . In some cases with treatment resistance to benzodiazepines, pentobarbital proved successful and treatment with antipsychotic agents was sometimes considered if severe delirium or hallucinations were reported [138, 139] . Finally, baclofen may be useful to treat GHB withdrawal, as it decreased severe withdrawal symptoms in one case without complications [134] .Also, baclofen is able to antagonize GHB selfadministration in mice [140] .
Because of the frequently observed treatment resistance of withdrawal symptoms to high dose benzodiazepine regiments and the many co-occuring complications during the standard GHB detoxification procedures, there has been a revision of the GHB detoxification protocol in the Netherlands, modelled as a scientific research program: the GHB-monitor of the Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA) [95] . The new protocol was based on a similar principle as the opioid withdrawal therapy with opioids [141] . The new detoxification protocol basically treats GHB withdrawal with pharmaceutical GHB (Xyrem ) in a daily titration and tapering scheme. The first results of this new detoxification procedure are promising: patients were started with a very high dose of pharmaceutical GHB (mean 16.9 g/day), which was then titrated to the usual dose of their illicit GHB and from there slowly tapered to zero [78] . Preliminary results indicate that 90% out of 226 patients have been detoxified successfully in this way [26, 95] . Titration with pharmaceutical GHB resulted in minor withdrawal symptoms with a mean of 26 on a scale of 0-140 and no delirium or psychosis were experienced by any of the patients.
However, this is a novel and pioneering detoxification procedure, unique to the world to our knowledge, and randomized controlled clinical trials (RCTs) have not been performed yet to provide scientific evidence for clinical efficacy of this treatment. For instance, comparisons with the benzodiazepines detoxification procedures are not available yet and no cost-effectiveness studies have been conducted.
Equally important, a considerable percentage of detoxified patients relapsed into GHB use within 3 months follow-up, only about one third had ceased GHB use completely, whereas the rest relapsed into incidental to frequent use and also turned back to some form of mental health or addiction treatment [95] . A necessary step by the researchers is to identify predictors that are important for relapse prevention, such as the high co-morbidity with other mental disorders that was found for many of these GHB addicted patients [95] . Fig. (3) . The putative mechanism whereby GHB increases dopaminergic activity in the mesocorticolimbic circuitry. As indicated by the bold arrow: GHB preferentially inhibits GABAergic neurons and the release of GABA in the ventral tegmental area through presynaptic GABAB receptors. As indicated by the dotted arrow: dopaminergic neurons are relatively left unscaved, thereby causing DA disinhibition. NAc, nucleus accumbens, VTA, ventral tegmental area, DA, dopamine.
CONCLUSIONS AND FUTURE DIRECTIONS
The available evidence shows that GHB, GBL and 1,4-BD are all substances with a considerable addiction potential and a potentially severe withdrawal symptomology. Most human evidence consists of case studies, hardly any systematic study or clinical studies were found of larger groups in addiction treatment. Similarly, most evidence for treatment efficacy is derived from case studies; virtually no solid RCTs for effective treatment are available. More appropriate studies are, however, underway. For instance in the Netherlands, where GHB and GBL use causes increasing health problems with rising numbers of users in addiction treatment, treatment guidelines have been developed [95] . These relatively large new groups of users in addiction treatment have also led to new research and scientific insights [79] . However, GHB addiction is still a relatively novel concept and is faced with new challenges in therapy and indicators for relapse prevention, similar issues that have been investigated a lot longer and more extensive for other addictive substances [142] [143] [144] Whereas GHB exerts some of its stimulating actions directly through the GHB receptor, most studies point towards the GABA system as the most probable candidate for GHB's actions on DA response, and thereby the circuitry for reward and addiction. However, this GABA B mediated DA disinhibition hypothesis must be tested further, by creating GHB receptor knockout mice or with the use of more specific agonists or antagonists. As it is, it does explain many of the elusive properties of GHB in the past, like the limited efficacy of treatment of GHB dependent patients with benzodiazepines and it offers promising avenues for GHB addiction treatment, like treatment with baclofen for instance or GABA B receptor antagonists. They may also prove to be useful in treating GHB overdose symptoms [135] .
One of the probable reasons for its increased use and, therefore, associated problems is the relative ease to manufacture GHB and easy accessibility of its precursors through internet (pure GBL). Until recently, GHB was classified as a Schedule II drug under the Dutch Opium Act, but its apparent great potential for harm and addiction has led the Dutch Minister of Health to execute another risk assessment. The overall risk potential of GHB use was now assessed as moderate to high and the government decided to upgrade GHB's status to a Schedule I drug ("hard drug") [8] . This will result in stronger law enforcement and the cracking down on illegal manufacture of GHB in the Netherlands. This shift in legal status might lead to an increase in the direct purchase and consumption of GBL as has already been suggested in studies from other countries where GHB's legal status became stricter, such as the United Kingdom or Switzerland [31] . As mentioned, GBL is a chemical with slightly different pharmacokinetics and a greater potency than GHB [58] . This may lead to differences in toxicity or addiction potential [59] . In addition, other analogues of GHB, such as gammahydroxyvaleric acid (GHV) for instance, have also been mentioned as possible replacements for GHB and they are sold as dietary supplements or other misleading products on the internet [145] . Because these substances differ in various aspects and toxicology, they might pose their own unique risks [146] .
For experts in the addiction field, it is important to keep track of these quickly changing customs in drug use nowadays, in light of the often unpredictable and severe effects of certain substances, such as GBL and GHB. For medical practitioners, it is important to realise the urgency of withdrawal symptoms associated with GHB addiction and together with new insights into treatment and relapse will hopefully lead to an improvement in handling the complications with this substance and its precursors.
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